Alain De Pover

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity

Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen et al. · Molecular Cancer Therapeutics · 2008 · 1.1K citations · Full text

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Sauveur-Michel Maira, Sabina Pecchi, Alan Huang et al. · Molecular Cancer Therapeutics · 2011 · 524 citations

Pharmacotherapy, Different Selectivity Profile, Chemical Biology +26

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Christine Fritsch, Alan Huang, Christian Chatenay‐Rivauday et al. · Molecular Cancer Therapeutics · 2014 · 462 citations

Pten Mutation, Somatic Pik3ca Mutations, Pharmacotherapy +18

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

Oliver Weigert, Andrew A. Lane, Liat Bird et al. · The Journal of Experimental Medicine · 2012 · 161 citations · Full text

Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent

Rita Andraos, Zhiyan Qian, Débora Bonenfant et al. · Cancer Discovery · 2012 · 126 citations · Full text

Crystal Structure, Molecular Biology, Signaling Pathway +21